Targeted Technology Funds
Venture capitalSan Antonio · Seed–Series A · 5 people tracked
Investment thesis
Targeted Technology Funds invests in early-stage life science and healthcare companies whose technologies can advance the practice of medicine and improve patient outcomes, as well as those that enhance the efficiency, cost, or functionality of developing and manufacturing life science products. The firm favors innovations with shorter time and lower cost to market that address compelling market needs offering the opportunity for enhanced returns. Investments span a broad range of healthcare categories, with particular emphasis on medical devices, life science tools, biotechnology, diagnostics, and specialty pharmaceuticals. The firm views its model as well suited to a healthcare environment that rewards better clinical outcomes and reduced costs.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from public directories
What they invest in
from 8 of 24 portfolio companiesHealthtech ×6Medical Devices ×5Biotech ×3Longevity ×1Robotics ×1
HQs:United States×6United Kingdom×1
Investments · 24 tracked
founders shown can be your intro pathBy year:2018 · 12015 · 23 dated
Smith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, serving orthopedic and sports medicine patients.
HealthtechMedical DevicesLondon, GB
PartnerAlan Dean· solo GP
Maker of the Spline-Fix External Fixator System for treating a range of bone fractures.
PartnerAlan Dean· solo GP
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Fred Dinger(Executive Officer, Director)
PartnerAlan Dean· solo GP
Medical device maker developing the Angel Catheter to prevent pulmonary embolism in critically ill patients; acquired by Mermaid Medical Group in 2018.
PartnerAlan Dean· solo GP
PartnerAlan Dean· solo GP
Provides technologies for detection, neutralization, and removal of endotoxin for bioresearch and bioprocess markets.
PartnerAlan Dean· solo GP
Developing the Surfacer Inside-Out Access Catheter System, a novel approach to central venous access.
PartnerAlan Dean· solo GP
Bluegrass Vascular develops the Surfacer Inside-Out Access Catheter System, a medical device using an "Inside-Out" approach to restore and preserve central venous access in patients with chronically occluded veins such as the superior vena cava.
HealthtechMedical Devices
John Gurley(Developer of the Inside-Out approach; Department of Cardiology, University of Kentucky)
PartnerAlan Dean· solo GP
Medical technology company focused on tissue regeneration and repair using proprietary scaffold materials.
PartnerAlan Dean· solo GP
Provides high-throughput, high-accuracy automated cellular patch clamp testing instruments for drug development research.
PartnerAlan Dean· solo GP
BiotechSan Antonio, US
James R. Garvin(Chief Executive Officer, President, Secretary and Treasurer)
PartnerAlan Dean· solo GP
Designs and manufactures instruments and devices for sinus surgery; acquired by Smith & Nephew in 2013.
PartnerAlan Dean· solo GP
HealthtechSan Antonio, US
David Schneider(Executive Officer, Director)Maggie Pemberton(Executive Officer)
BoardPaul Castella(Executive Officer, Director)Jim Traa(Director)John Pinsent(Director)Joe Brennan(Director)
PartnerAlan Dean· solo GP
Medical device company providing the neoClose Trocar Port Closure System for laparoscopic and minimally invasive surgery.
PartnerAlan Dean· solo GP
Oxnard, US
Vito SAN FILIPPO(Executive Officer)MARIANNE THERESA CRONIN(Executive Officer, Director)
PartnerAlan Dean· solo GP
Enhances drug discovery by optimizing protein solubility and stability; acquired by InventaBioTech in 2016.
PartnerAlan Dean· solo GP
PartnerAlan Dean· solo GP
StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties.
BiotechHealthtechLongevityMedical DevicesSan Antonio, US
Jean Cheever(Director)Chen Xiao-Dong(Director)Mark D Horsey(Executive Officer)Robert Hutchens(Director)John W Feik(Director)Steven Davis(Co-founder)
PartnerAlan Dean· solo GP
Xenex builds pulsed Xenon UV light disinfection robots that deactivate pathogens missed during manual cleaning, used by hospitals to reduce environmental contamination and healthcare-associated infections.
HealthtechMedical DevicesRobotics
Mark (Tuck) Stibich(Co-founder)Julie Stachowiak(Co-founder)Morris Miller(Co-founder & CEO)Mark "Tuck" Stibich(Founder & Chief Scientific Officer)
PartnerAlan Dean· solo GP
World leader in UV room disinfection robot systems for healthcare facilities.
PartnerAlan Dean· solo GP
Exits · 7
IPOs and acquisitions across the tracked portfolioSmith+NephewNYSE: SNNBiO2 Medical, Inc.acq. by Mermaid Medical GroupENTrigue Surgical, Inc.acq. by Smith+NephewSantalis Pharmaceuticals, Inc.acq. by TFSSoluble Bioscience, LLCacq. by InventaBioTechVidacareacq. by TeleflexViroXis Corporation, Inc.acq. by TFS
Portfolio news
latest coverage across their companiesAerin Medical · mpo-mag.com · Feb 19, 2025
Frequently asked questions
- What stage does Targeted Technology Funds invest at?
- Targeted Technology Funds invests at the Seed, Series A stages.
- What sectors does Targeted Technology Funds focus on?
- Targeted Technology Funds focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Targeted Technology Funds located?
- Targeted Technology Funds is headquartered in San Antonio, US.
Similar investors
Amadeus Capital Partners is a deep tech investor backing companies across the themes of Intelligence, Human potential, and the Planet.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Black Opal Ventures is a venture capital firm founded in 2021 by Tara Bishop and Eileen Tanghal, focused on investing at the intersection of healthcare and technology.